Literature DB >> 18418091

An attractive therapeutic target, mTOR pathway, in ALK+ anaplastic large cell lymphoma.

Jeong Hee Cho-Vega1, Francisco Vega, L Jeffrey Medeiros.   

Abstract

Entities:  

Year:  2008        PMID： 18418091     DOI： 10.1097/PAP.0b013e318166139f

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN： 1072-4109            Impact factor:   3.875


× No keyword cloud information.
  2 in total

Review 1.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

2.  Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.

Authors:  V Atsaves; R Zhang; D Ruder; Y Pan; V Leventaki; G Z Rassidakis; F X Claret
Journal:  Leukemia       Date:  2015-05-19       Impact factor: 11.528
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.